Darovasertib

Overview

Darovasertib (LXS196) is a potent, selective and orally active protein kinase C ( PKC ) inhibitor, with IC 50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα , PKCθ and GSK3β, respectively. Darovasertib has the potential for uveal melanoma research.

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Digestive System Inflammation | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > TGF-beta/Smad | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > PKC

Product Information

• Catalog No.: HY-101569
• CAS No.: 1874276-76-2
• Molecular Formula: C22H23F3N8O
• Molecular Weight: 472.47
• Purity: 99.78%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution
• Availability: In-stock

Source

Original product source